COX-2 Inhibitors
Okay, I'm hoping SOMEONE comments on this post, but since it seems noone even visits the page, that seems unlikely....
The NEJM issue features the articles that recently described the increased cardiovascular risk of Vioxx leading to an industry chaos.
The Lancet article is one of many that details these risks long before they were talked about openly, thus precipitating the fury with Merck and the FDA.
The JCI article gives a hint of possible ways around the problems.
Anyone want to stand up for Bayer?
posted by Michael A. Seidman @ 2:43 PM
0 Comments:
Post a Comment
<< Home